🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Registration is now open for the 4th Annual It Takes Guts Fundraiser Pickleball Tournament presented by Southern Pickleball, benefitting the Gastric Cancer Foundation. Mark your calendars for November 21-23 in Rome, Georgia! pickleballtournaments.com/tournaments/E6…

Gastric Cancer Foundation Board Member Hans Rueffert shares some of the benefits of biomarker testing as well as resources available at TestYourBiomarkers.org. Hans Rueffert Test Your Biomarkers

Artificial intelligence could significantly improve the accuracy of endoscopy in detecting gastric cancer, argued a team of researchers in @cureusmedical. cureus.com/articles/35227…

Mutations in four genes have been linked to poor prognosis in gastric cancer and could help guide personalized treatments in the future. The research was presented at Digestive Disease Week earlier this month. insideprecisionmedicine.com/topics/oncolog…

A study by Cleveland Clinic found that many early-onset gastric cancers occur in the “lumen,” the inner passage where food travels through, highlighting the importance of understanding how diet, environment and other factors might influence risk. consultqd.clevelandclinic.org/luminal-gi-can…

Today is the final day of the ASCO 2025 Annual Meeting. Dr. Lizzy Smyth of Oxford University Hospitals NHS Foundation summarizes the key gastric cancer updates presented at #ASCO25 in this video. x.com/ginursesconnec…

Treating gastric cancer patients before and after surgery with the immunotherapy drug Imfinzi (durvalumab) and FLOT chemotherapy produced a 29% better event-free survival rate than chemo alone, according to a trial presented at #ASCO25. ascopost.com/news/june-2025…

A trial presented at #ASCO25 “defines a new paradigm” for treating gastric cancer by showing the value of including the immunotherapy drug Imfinzi (durvalumab) in early-line treatment, said Yale doctor Pamela Kunz. Via FiercePharma.fiercepharma.com/pharma/asco-as…

“At ASCO, Enhertu cements growing role in stomach cancer care” via BioPharma Dive. #ASCO25 biopharmadive.com/news/astrazene…

We’re excited to support Patient Advocacy Organization (PAO) Action Week from June 9–13. This grassroots initiative is dedicated to raising awareness and connecting patients to relevant PAOs like ours. Follow #PAOActionWeek and visit bit.ly/4bJXdU6 to learn more.

Last month, we partnered with @cancercare to present an information-packed webinar, “Advances in the Treatment of Gastric Cancer." If you missed it, the webcast recording is now available. Listen at the link below. cancercare.org/connect_worksh…

Because people of Asian descent face a high risk of gastric cancer due to H. pylori, they could benefit from regular screening for the infection, argues Martin McCarter of CU Cancer Center.news.cuanschutz.edu/cancer-center/…

Second-line treatment with Enhertu (trastuzumab deruxtecan) from Daiichi Sankyo led to a significant and meaningful improvement in overall survival when compared to chemotherapy in a phase 3 trial in patients with HER2-positive gastric cancer. onclive.com/view/t-dxd-imp…

A combination of paclitaxel administered to the peritoneal cavity and standard IV-administered paclitaxel plus S-1 extended survival in patients whose cancer had spread to the peritoneum, according to a study presented at ASCO GI earlier this year. ascopost.com/issues/march-2…

Why is stomach cancer on the rise in young adults, especially women? And what can people do to minimize their risk? City of Hope oncologist Yanghee Woo weighs in on those questions. cityofhope.org/hope-matters-b…

The detection of gastric cancer in its earliest stages, when the probability of treatment success is highest, has increased by more than 50% in the last 20 years. Here’s more on this positive trend, via Healio. healio.com/news/gastroent…

Adding the immune-boosting drug Tecentriq (atezolizumab) to Herceptin (trastuzumab) plus chemotherapy showed promise in a trial in patients with ERBB2–positive gastric cancer. Via CancerNetwork® cancernetwork.com/view/atezolizu…

A new combination therapy incorporating Keytruda (pembrolizumab) into treatment for HER2-positive gastric cancer was recently approved. Memorial Sloan Kettering Cancer Center oncologist Yelena Janjigian discusses how to manage side effects. Via Targeted Oncology targetedonc.com/view/managing-…

New guidance from the American Gastroenterological Association (AGA) suggests that endoscopic screening and surveillance of precancerous conditions in people who face a high risk of gastric cancer could reduce incidence and mortality. mdedge.com/gihepnews/arti…

Major developments in research and clinical practice are helping address the biggest challenges in gastric cancer, say oncologists at Sylvester Comprehensive Cancer Center, part of Miller Medicine. news.med.miami.edu/addressing-the…